Biotivia appoints Dr Abbas Green as Chief Medical Officer

Biotivia appoints Dr Abbas Green as Chief Medical Officer

Biotivia, a world leading developer of resveratrol based supplements for the functional food and medical markets, has announced the appointment of Dr Abbas Green as their new Chief Medical Officer.

Biotivia, a world leading developer of resveratrol based supplements for the functional food and medical markets, has announced the appointment of Dr Abbas Green as their new Chief Medical Officer.

Dr Green qualified as a physician at the University Of Wales College Of Medicine, Cardiff, UK. His post-graduate training was in general practice and urology. He is board certified for both those specialties. Dr Green also has a qualification in urology from the UK's Royal College of Surgeons and is a fellow of the European Board of Urology and is trained in nutritional medicine and naturopathy.

At Biotivia, Dr Green is responsible for advising on medical and pharmaceutical matters and developing natural formulations in the areas of men's health with a focus on endocrine related conditions and prostate health. As a specialist in urology, Dr Green has world-class training and experience in prostate and erectile dysfunction health issues. He has received numerous research grants and awards in the field of men's health.

In addition to his medical qualifications, Dr Green has a diploma in naturopathic medicine. He is a regular lecturer at naturopathic colleges and clinics, and also lectures at St Georges' Hospital Medical School, London, for the faculty of community medicine.

James Betz, Founder and CEO of Biotivia said: "We are extremely excited to have Dr Abbas join us at Biotivia. With his level of experience and years of being one of the best medical practitioners in his field, we hope to develop a vast range of all natural resveratrol supplements that will both compliment and improve your lifestyle."

Dr Green's combination of family physician qualifications, urology, and nutritional medicine specializations, and his unique naturopathic insights make him a perfect fit for the position of Chief Medical Officer at Biotivia. One of Dr Green's formulations for prostiatitis, which is being developed in conjunction with the resveratrol research team at Biotivia, is being prepared for human trials at three medical facilities in Europe. Dr Green advises the Biotivia board on safety and efficacy regarding new formulations and serves as Biotivia's liaison to the medical community.

Dr Green will also be involved in resveratrol and pterostilbene research projects. Biotivia's products have been used in numerous clinical studies throughout the world, including at, but not all: The University of Queensland Diamantina Institute, Albert Einstein Medical College, University of Northumbria, University of Ferrara and Stoney Brook Medical College.

Betz continues: "With this level of expertise and our collaborations with these top medical institutes we hope to develop some life changing resveratrol and pterostilbene based supplements that will benefit many. Our ongoing trials are proving that natural remedies are just as beneficial to the health as traditional medical practices."

To read more about Biotivia please visit

About Biotivia LLC

Biotivia was established in 1992 in Vienna, Austria as a supplier of natural raw materials and botanicals to the supplement and functional food industries and to researchers and scientific institutions worldwide. The company evolved into one of the world's leading developers and suppliers of potent nutritional supplements and skin care therapies, with most of their products centered around the use of concentrated resveratrol and complementary botanical extracts.

Biotivia presently has US offices in New York, Los Angeles, Kansas City and international offices in the UK, Spain, Austria, Denmark, Italy, Germany, Singapore, Xi'an, China and Mumbai, India.

Beyond its strong consumer base, the company currently supplies researchers, physicians and scientists at Harvard, Stanford, Yale, Georgetown, The Albert Einstein Medical Center, University of Texas, M.D. Anderson Cancer Center and the University of California. Transmax and Bioforte in particular are being explored by several major universities as a possible treatment for a variety of conditions that seriously impair the health and well being of millions of people around the world. Biotivia recently signed an agreement to supply Transmax to the University of Ferrara for use in three human clinical trials in Italy and Egypt on its possible use by Thalassemia sufferers.

Biotivia's resveratrol products, Transmax and Bioforte, have been independently assessed by Consumer Labs, the leading American quality watchdog, and were deemed both 'most potent' and 'best value'.

Most of Biotivia's other supplements have been certified Vegan by the American Vegetarian Association.

Neither Florativia nor any Biotivia product has been shown to prevent any yeast infections. Florativia is not intended to diagnose, prevent, treat or cure any disease. The statements herein have not been reviewed or approved by the US FDA. All Biotivia supplements are manufactured in state of the art FDA inspected pharmaceutical facilities in accordance with CGMP USP standards.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.